Evidence map›Paper›PMID 33097085›Full record

Trial reportClinical epigenetics2020

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.

Mu-Chen Zhang, Ying Fang, Li Wang, Shu Cheng, Di Fu, Yang He, Yan Zhao, Chao-Fu Wang, Xu-Feng Jiang, Qi Song and 2 more

2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical epigenetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01852435 phase3unknown statusnot on this map

A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B

TypeinterventionalSponsorRuijin HospitalRan2013 to 2018Enrolled648ConditionsDiffuse Large B-cell Lymphoma, Follicular Lymphoma Grade 3BArmsR-CEOP-70, R-CEOP-90, R-CHOP-50
NCT02753647 phase2unknown statusnot on this map

A Prospective, Single Arm, Open-label, Phase II Study of Chidamide in Combination With R-CHOP in the Treatment of de Novo, Elderly, High-risk Diffuse Large B-cell Lymphoma

TypeinterventionalSponsorRuijin HospitalRan2016 to 2019Enrolled49ConditionsDiffuse Large B-cell LymphomaArmsRituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Mechanisms of HDACs in cancer development.Frontiers in immunology · 2025
    Review
  14. Review
  15. Review
  16. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Mu-Chen ZhangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ying FangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li WangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shu ChengShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Di FuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yang HeShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yan ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao-Fu WangDepartment of Pathology, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xu-Feng JiangDepartment of Nuclear Medicine, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qi SongDepartment of Radiology, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Peng-Peng XuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China. pengpeng_xu@126.com.
Wei-Li ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine At Shanghai, Ruijin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhao.weili@yahoo.com.ORCID 0000-0003-1704-4491
Shanghai Jiao Tong University · CNRuijin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma activities and can be applied to treat DLBCL. This study aimed to evaluate efficacy and safety of oral HDACI tucidinostat (formerly known as chidamide) plus R-CHOP (CR-CHOP) in elderly patients with newly diagnosed DLBCL (International Prognostic Index ≥ 2).

resultsAmong 49 patients, the complete response rate was 86%, with overall response rate achieving 94%. The 2-year progression survival (PFS) and overall survival (OS) rates were 68% (95% CI 52-79) and 83% (95% CI 68-91). Comparing with historical control (NCT01852435), the 2-year PFS and OS rates of double-expressor lymphoma phenotype (DEL) were improved, and negative prognostic effect of histone acetyltransferases CREBBP/EP300 mutations was also mitigated by CR-CHOP. Grade 3-4 neutropenia was reported in 171, grade 3-4 thrombocytopenia in 27, and grade 3 anemia in 11 of 283 cycles. No grade 4 non-hematological adverse event was reported.

conclusionCR-CHOP is effective and safe in elderly patients with newly diagnosed DLBCL. Relevance of DEL phenotype and molecular biomarkers on CR-CHOP response warrants further investigation in DLBCL. Trial registration ClinicalTrial.gov, NCT02753647. Registered on April 28, 2016.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBiomarkersCase-Control StudiesCREB-Binding ProteinCyclophosphamideDoxorubicinE1A-Associated p300 ProteinEpigenomicsFemaleHistone Deacetylase InhibitorsHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedBCL2 protein, humanBenzamidesBiomarkersCREB-Binding ProteinCREBBP protein, humanCyclophosphamideDoxorubicinE1A-Associated p300 ProteinEP300 protein, humanHBI-8000Histone Deacetylase InhibitorsMYC protein, humanPrednisoneProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycPyridinesR-CHOP protocolRituximabVincristineCREBBP/EP300Diffuse large B-cell lymphomaDouble expressor lymphomaHistone deacetylase inhibitorTucidinostat

Identifiers

PMID33097085
PMCPMC7585299
OpenAlexW3094446310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.